A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF INCA033989 VERSUS BEST AVAILABLE THERAPY IN PARTICIPANTS WITH ESSENTIAL THROMBOCYTHEMIA AND A CALR MUTATION PREVIOUSLY TREATED WITH CYTOREDUCTIVE THERAPY (EXCALIBUR-ET2)
- Registry ID
- INCA033989-304
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- INCYTE CORPORATION
- Last update
- 2026-07-23
Conditions
- ESSENTIAL THROMBOCYTHEMIA
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-COMPARATOR-CONTROLLED CLINICAL
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BOMEDEMSTAT (MK-3543) VERSUS
HYDROXYUREA IN CYTOREDUCTIVE THERAPY NAÏVE ESSENTIAL THROMBOCYTHEMIA
PARTICIPANTS
- A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-COMPARATOR-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BOMEDEMSTAT (MK-3543/IMG-7289) VERSUS BEST AVAILABLE THERAPY (BAT) IN PARTICIPANTS WITH ESSENTIAL THROMBOCYTHEMIA WHO HAVE AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
- A SINGLE-ARM, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF ROPEGINTERFERON ALFA-2B-AJFT (P1101) IN ADULT PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
- A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED STUDY TO ASSESS PHARMACOKINETICS AND COMPARE THE EFFICACY, SAFETY, AND TOLERABILITY OF P1101 VS ANAGRELIDE AS SECOND LINE THERAPY FOR ESSENTIAL THROMBOCYTHEMIA (SURPASS ET): THE CORE STUDY AND ITS EXTENSION STUDY
View on source registry